53results about "Haemofiltration" patented technology

Disposable set for an extracorporeal blood treatment apparatus including a blood circuit comprising a filtration unit, a blood withdrawal line including a blood pump tract configured to be engaged by a blood pump, a blood return line, and an infusion line extending between a first end connected to the blood withdrawal line upstream the blood pump tract, and a second end for connection to an infusion substance source: the blood pump tract is interposed between the filtration unit and the first end of the infusion line. The disposable set further comprises a pressure damper arranged towards or at the first end of the infusion line, the pressure damper being configured to prevent, or reduce an amount of, the access negative pressure to extend in the infusion line upstream the pressure damper.

Methods and apparatuses for blood clot aspiration. Described are fluid management components and assemblies for blood clot extraction from a patient's body and for filtering blood and recirculating blood back into the patient's body.

In accordance with at least one aspect of this disclosure, a method for preparing a patient for a diagnostic procedure and / or for receiving a therapy using a disease targeted drug is provided. The method can include the steps of a) identifying one or more soluble targets detectable in plasma of the patient; and b) extracorporeally removing the soluble targets from the plasma of the patient. Extracorporeally removing the soluble targets from the plasma of the patient can include using plasmapheresis or immunoadsorption to prepare a patient for a procedure using disease targeted treatment or diagnostics. Additionally, or alternatively, dose modulation can be used to proportionally increase the concertation of the diagnostic / treatment agent relative to the concentration of the soluble target in the blood, improving the outcome treatment and diagnostic procedures over conventional methods.

The artificial diuretic device is wearable by a patient (H) and comprises a reusable machine (2) and a disposable unit (3), which is completely filled with a treatment liquid (Lt) before use.

The invention relates to a blood treatment device configured to dephosphorylate extracellular adenosine triphosphate (ATP), adenosine diphosphate (ADP), adenosine monophosphate (AMP) and / or lipopolysaccharide (LPS) in the blood of a patient in need thereof in an extracorporeal blood circuit, wherein the device comprises a matrix having alkaline phosphatase (AP) immobilized thereon. The invention further relates to an extracorporeal blood circuit comprising a blood treatment device of the invention and to the blood treatment device for use as a medicament or to methods of treating an infection, preferably a blood or systemic infection, such as sepsis, and / or for the treatment of sepsis-associated acute kidney injury (AKI).

A soft cassette includes a body including a flexible material and first and second component. The body defines first and second lumens and first and second chambers. The first lumen extends between first and second ends. The first chamber is in the first lumen such that fluid passing through the first lumen passes through the first chamber. The second lumen is fluidly connected to the first lumen at a first junction between the first end and the first chamber and a second junction between the second end and the first chamber such that fluid passing through the second lumen bypasses the first chamber. The second chamber is in the second lumen. The first component is on a first side of the second chamber and includes a first ferromagnetic metal or magnet. The second component is on a second side of the second chamber and includes a second ferromagnetic metal magnet.

The application discloses an ultrafiltration permeation regulation method and device based on a gradient sponge structure dialysis membrane and relates to the technical field of hemodialysis. An intelligent response membrane assembly containing a nonlinear aperture gradient is constructed; a signal is collected and a concentration polarization critical index is calculated; when the threshold value is exceeded, a multi-frequency coupling pulse control instruction containing a mechanical resonance excitation waveform and a phase reverse matching osmotic pressure oscillation waveform is generated; mechanical resonance excitation is applied to the blood side to induce membrane layer micro-breathing deformation, and an osmotic pressure oscillation waveform is injected into the dialysate side to form a reverse solute diffusion field; microgel deformation feedback signals are monitored in real time, waveform parameters are dynamically adjusted, and the concentration polarization critical index is returned to a safe interval until the ultrafiltration flux is adaptively regulated. The device comprises an intelligent gradient membrane assembly, a fluid power regulation module, an osmotic pressure wave generation module, a sensing feedback array and a central processing unit, can effectively inhibit membrane pollution and concentration polarization, and improves the system operation stability.

Methods and apparatuses for blood clot aspiration. Described are fluid management components and assemblies for blood clot extraction from a patient's body and for filtering blood and recirculating blood back into the patient's body. Also disclosed is a vent system including a common vent line (1508) to fluidly couple a reservoir (1403), a clot capture chamber (1405) and a blood return syringe (1409).

A peritoneal dialysis system includes (i) a fill container, and (ii) an energizing unit that removably accepts the fill container, the energizing unit including a sterilization source so configured and arranged relative to the fill container when accepted by the energizing unit to place fluid within the fill container in a physiologically safe condition for delivery to the peritoneal cavity of a patient.

Methods, systems, and apparatuses for integrating medical device data are disclosed. In an example embodiment, an integration engine receives infusion therapy progress data from an infusion pump related to a patient identifier and receives renal failure therapy progress data from a renal failure therapy machine related to the same patient identifier. The integration engine determines fluid balance data based on a difference between at least some of the infusion therapy progress data and at least some of the renal failure therapy progress data and causes a combination user interface to display a trend of the fluid balance data within a fluid balance timeline. The integration engine determines when the trend of the fluid balance data exceeds a fluid balance limit and causes a fluid balance alarm or alert to be provided.

The present application belongs to the technical field of biomedical engineering industry, especially a blood purification device and method, aiming at the problem that most of the existing blood purification devices adopt single-layer filter structure, which is difficult to simultaneously and efficiently intercept large-particle blood clots and small impurities, resulting in insufficient purification precision or affecting purification efficiency due to filter membrane blockage, the present application proposes the following scheme, which comprises a device main body, a shell cover is rotatably installed on the front surface of the device main body through a hinge, an observation window is fixedly embedded on the shell cover for real-time observation of the blood purification process inside the device, and a control module is fixedly arranged on the outer wall of the device main body through bolts. The present application realizes a three-stage purification mode of "coarse filtration, fine filtration and centrifugal strengthening", improves the rotation stability of the centrifugal mechanism, accurately controls the purification environment temperature, real-time feedbacks the blood purification index, ensures the safe and convenient operation, and meets the high-precision and high-safety requirements of clinical blood purification.

A bioartificial liver support system for continuous and discontinuous procedures to provide liver support to a patient, comprising: a chamber containing biomass; a tubular system having multiple circuits adapted to provide independent circuit operation to an apheresis machine or patient; and a monitoring device having one or more sensors adapted to collect, record, analyze, download, and / or store data from the system.

A concentration of a substance to be removed in target liquid on an upstream side of a joining point of a second flow path in a first flow path is measured as a first concentration C1 based on an output signal of a first concentration sensor. A concentration of the substance to be removed in target liquid on a downstream side of the joining point of the second flow path in the first flow path is measured as a second concentration C2 based on an output signal of a second concentration sensor. When a difference ΔC between the first concentration C1 and the second concentration C2 is less than a concentration difference threshold, at least one of decreasing degree of opening of a first flow rate control valve and increasing degree of opening of a second flow rate control valve is executed.

The present invention relates to an extracorporeal device or an ex vivo organ perfusion device comprising an inline monitoring method or device for measuring cell free nucleosomes, particularly an apheresis device comprising a monitoring method or device for measuring cell free nucleosomes in the blood of a subject.

The present disclosure relates to semipermeable membranes comprising a base membrane and a coating with a vinyl polymer derived from vinyl monomers carrying an acid group and grafted onto the surface of the base membrane by radiation induced graft copolymerization (RIGC), thereby introducing a coating carrying negative charges. The coated membranes are especially suitable for blood purification applications as they are characterized by an increased selectivity and excellent blood compatibility and an excellent hemocompatibility due to the careful selection of the vinyl monomers used for the coating process and the introduction of negative charges. The invention also relates to a production process for said coated membranes and to their use in hemodialysis devices and in medical applications such as extracorporeal blood purification.

The invention relates to a compression cuff for an arteriovenous fistula comprising a rigid support element (5) through which an orifice (12) passes, a flexible band (2) connected to one end (10) of the support element, and a closure device (3) for opening or closing the cuff. The support element and the band define a rounded enclosure when the cuff is in the closed position. The cuff also includes a stem (13) mounted to slide in translation within the orifice of the rigid support element, without being able to rotate relative to said element. The stem has two opposite ends, an upper end located outside the enclosure and a lower end located inside the enclosure. The cuff further includes a compression pad connected to the lower end of the stem and means for locking the translational movement of the stem. Figure for the abstract: Fig. 2

The invention relates to a method for determining an actual pumping rate and / or for calibrating a blood pump (101) of a blood treatment device (100), which is connected to an extracorporeal blood circuit (300). The method according to the invention comprises, as the first of a plurality of steps, the providing of a blood pump (101) of a blood treatment device (100) or the establishment of a signal connection to a blood pump (101). For the purpose of the blood treatment of the patient, the blood pump (101) has at least one first source (200) for a fluid and at least one first line (301) of an extracorporeal blood circuit (300), said first line following the first source (200) downstream of the first source, or can be or is connected to such. Furthermore, the blood pump (101) has at least one first receptacle (400) for receiving fluids of the first source (200), the receptacle having a fluid connection to the first line (301), or can be or is connected to such a receptacle. The receptacle (400) is arranged on or against a first weighing apparatus (141) in such a way that the weight of the receptacle (400) or of the content of the receptacle can be determined by means of the weighing apparatus (141).

A measuring apparatus and artificial diuresis device wearable by a patient (H) and comprising a reusable machine (2) and a disposable unit (3).

A medical infusion fluid handling system, such as an automated peritoneal dialysis system, may be arranged to de-cap and connect one or more lines (such as solution lines) with one or more spikes or other connection ports on a fluid handling cassette. This feature may reduce a likelihood of contamination since no human interaction is required to de-cap and connect the one or more lines and the one or more spikes. For example, the automated peritoneal dialysis system may include a carriage arranged to receive the one or more lines each having a connector end and a cap. The carriage may move along a first direction so as to move the connector ends of the one or more lines along the first direction, and a cap stripper may be arranged to engage with the caps on the solution lines on the carriage. The cap stripper may move in a second direction transverse to the first direction, as well as to move with the carriage along the first direction.

The present disclosure relates to a fluid treatment patient system for a patient, comprising at least one protein dialysis circuit to remove water soluble and protein bound toxins, especially wherein the protein is preferably albumin, wherein the dialysis circuit comprises at least one or two dialyzers, wherein the circuit is configured to perform the dialysis at least such that a continuous recirculation and purification of the protein containing dialysate, preferably albumin containing dialysate, is performed, especially wherein these treatments are preferably performed with two dialyzers or one single dialyzer, and wherein the membrane areas is sufficient for toxin elimination.

Methods and apparatuses for blood clot aspiration. Described are fluid management components and assemblies for blood clot extraction from a patient's body and for filtering blood and recirculating blood back into the patient's body.

Circulating cell clusters found in subjects with cancer, autoimmune conditions, infections, or other diseases, can be trapped or disrupted by filtering them with an intra- or extracorporeal device and, in some cases, exposing them to a substance, such as enzyme, that reduces intercellular adhesion.

The present invention relates to a method for removing protein-bound uremic toxins from the blood of a patient who requires it. The method involves introducing a substitution substance, selected from (C6-C12) fatty acids, salts of (C6-C12) fatty acids, precursors of the said (C6-C12) fatty acids, or mixtures thereof, into the blood. The substitution substance replaces the protein-bound uremic toxins, thereby releasing unbound uremic toxins into the blood. The unbound uremic toxins are then removed from the blood by any method, including dialysis. The method according to the present invention is effective with low concentrations of the substitution substance at plasma concentrations ranging from 0.5 to 3 mM.

An extracorporeal and drug delivery system includes: (i) a renal failure treatment machine operable with a blood filter in fluid communication with an arterial line and a venous line, the machine including: (a) an effluent pump for pumping effluent from the blood filter at an effluent flow rate; and at least one of: (b) a dialysis fluid pump for pumping dialysis fluid to the blood filter at a dialysis fluid flow rate; (c) a pre-dilution pump for pumping replacement fluid into the arterial line at a pre-dilution flow rate; or (d) a post-dilution pump for pumping replacement fluid into the venous line at a post-dilution flow rate; (ii) an infusion pump operable to deliver an intravenous ("IV") drug to a patient at an IV drug flow rate; and (iii) a coordination logic implementer configured to adjust the IV drug flow rate based on an amount of the IV drug removed via the effluent flow rate.

A method is used to operate a device for extracorporeal blood treatment. The device can perform haemodialysis and hemodiafiltration. During hemodiafiltration, blood is delivered through a blood side of a dialyzer by an electric blood pump. Substituate is delivered by an electric substituate pump. A delivery volumetric flow of the electric substituate pump is adjusted in such a way that a current consumption of the electric blood pump remains within predefinable limit values.

The present invention relates to a dialysis machine comprising a connection system (450) for connecting a dialysate supply source (40) to a dialysate delivery system (51), the connection system (450) comprising a first section (451) having a conduit (4510) with a first connection device (4511) at one end to a first dialysate supply source and a second connection device (4512) at the other end to allow serial connection of the first section and the second section. and a second section (452) having a conduit (4520) with a connecting device (4521) at one end connectable to a second connecting device (4512) of the first section (451), the first section (451) being disconnectable from the second section (452) such that in a disconnected state of the first section (451) from the second section (452), the connecting device (4521) of the second section (452) is connectable to a second dialysate supply source. The present invention also relates to a corresponding method.